Trials / Completed
CompletedNCT02452112
Efficacy and Safety of 5% Lidocaine Patch With Placebo Patch in Subjects With Herpes Zoster Associated Pain
An Open-Label, Single and Multiple-Dose, Two-Period, Consecutive Study in Healthy Chinese Subjects to Assess the Pharmacokinetic Profiles, Safety and Tolerability of Lidocaine Patch 5%.LIG13-CN-101 Study
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 243 (actual)
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of 5% lidocaine patch, following placebo or active patch applications in placebo insensitive subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5% Lidocaine patch | 5% Lidocaine patch to be placed on the site of pain |
| DRUG | Placebo | Placebo patch to be placed on the site of pain |
Timeline
- Start date
- 2014-11-02
- Primary completion
- 2015-12-30
- Completion
- 2016-10-30
- First posted
- 2015-05-22
- Last updated
- 2017-11-14
Locations
21 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02452112. Inclusion in this directory is not an endorsement.